Retinal imaging in an era of open science and privacy protection.

Journal: Experimental eye research
PMID:

Abstract

Artificial intelligence (AI) holds great promise for analyzing complex data to advance patient care and disease research. For example, AI interpretation of retinal imaging may enable the development of noninvasive retinal biomarkers of systemic disease. One potential limitation, however, is government regulation regarding retinal imaging as biometric data, which has been recently under debate in the United States. Although careful regard for patient privacy is key to maintaining trust in the widespread use of AI in healthcare, the designation of retinal imaging as biometric data would greatly restrict retinal biomarker research. There are several reasons why retinal imaging should not be considered biometric data. Unlike images of the iris, high quality images of the retina are more difficult to obtain, requiring specialized training and equipment, and often requiring pupil dilation for optimal quality. In addition, retinal imaging features can vary over time with changes in health status, and retinal images are not currently linked to any large identification databases. While the protection of patient privacy is imperative, there is also a need for large retinal imaging datasets to advance AI research. Given the limitations of retinal imaging as a source of biometric data, the research community should work to advocate for the continued use of retinal imaging in AI research.

Authors

  • Nayoon Gim
    Department of Ophthalmology, University of Washington, Seattle, WA, United States.
  • Marian Blazes
    From the Department of Ophthalmology, University of Washington, Seattle, Washington.
  • Clara I Sanchez
  • Luca Zalunardo
    Icare USA Inc, Raleigh, NC, USA.
  • Giulia Corradetti
    Doheny Eye Institute, Pasadena, CA, USA.
  • Tobias Elze
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts; Complex Structures in Biology and Cognition, Max Planck Institute for Mathematics in the Sciences, Leipzig, Germany. Electronic address: tobias-elze@tobias-elze.de.
  • Naoto Honda
    Nidek, CO. LTD, Aichi, Japan.
  • Nadia K Waheed
    New England Eye Center, Tufts Medical Center, Boston, Massachusetts.
  • Anne Marie Cairns
    Optos Plc, Dunfermline, Scotland, United Kingdom.
  • M Valeria Canto-Soler
    CellSight Ocular Stem Cell and Regeneration Research Program, Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado, Aurora, CO, USA.
  • Amitha Domalpally
    Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.
  • Mary Durbin
    Heru, Inc., Miami, Florida.
  • Daniela Ferrara
    Genentech, Inc., South San Francisco, California.
  • Jewel Hu
    Doheny Eye Institute, Pasadena, CA, USA.
  • Prashant Nair
    Proceedings of the National Academy of Sciences, Washington, DC, USA.
  • SriniVas R Sadda
    Doheny Image Analysis Laboratory, Doheny Eye Institute, Los Angeles, CA, USA.
  • Tiarnan D L Keenan
    Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
  • Cecilia S Lee
    Department of Ophthalmology, University of Washington, Seattle, Washington, USA.